Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1436172 | 0.85 | SLC7A5 (0.49) | KMT2AMAPTLOXL2RAB9AKDM4E | |
| SCHEMBL31439643 | 0.84 | SLC7A5 (0.48) | KMT2AMAPTLOXL2RAB9AKDM4E | |
| SCHEMBL3826655 | 0.83 | MAPT (0.47) | TDP1MEN1KMT2ACA1CA2 | |
| SCHEMBL8249383 | 0.83 | MAPT (0.43) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2036336 | 0.82 | NPC1 (0.54) | TDP1MEN1KMT2ACA1CA2 | |
| SCHEMBL16061270 | 0.80 | CA1 (0.43) | TDP1MEN1KMT2ACA1CA2 | |
| SCHEMBL2198776 | 0.79 | KMT2A (0.44) | MEN1KMT2AMAPTESR2HTT | |
| SCHEMBL11811932 | 0.79 | MAPT (0.54) | MEN1KMT2ACA1CA2MAPT | |
| SCHEMBL4444431 | 0.77 | CA1 (0.70) | TDP1MEN1KMT2ACA1CA2 | |
| SCHEMBL10537396 | 0.77 | CA1 (0.70) | TDP1MEN1KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008856-A1 | Treatment of septic shock | KAZMIERSKI WIESLAW MIECZYSLAW (US) | 2003-01-09 | — | — | US | claimed |
| US-20020091113-A1 | Treatment of septic shock | MOLICHEM MEDICINES, INC. | 2002-07-11 | — | — | US | claimed |
| EP-0697864-A1 | TREATMENT OF SEPTIC SHOCK | MOLICHEM MEDICINES, INC. (US) | 1996-02-28 | — | — | EP | claimed |
| WO-1994026263-A2 | USE OF A TRANSITION METAL COMPLEX FOR THE TREATMENT OF SEPTIC SHOCK | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-24 | — | — | WO | claimed |
| US-8278243-B2 | Laser imaging | DATALASE LTD. (GB) | 2012-10-02 | — | — | US | disclosed |
| US-20100075848-A1 | Laser Imaging | DATALASE LTD. (GB) | 2010-03-25 | — | — | US | disclosed |
| US-7022734-B2 | Treatment of septic shock | MOLICHEM MEDICINES, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030008856-A1 | Treatment of septic shock | KAZMIERSKI WIESLAW MIECZYSLAW (US) | 2003-01-09 | — | — | US | disclosed |
| US-6465511-B1 | SUCH AS DIETHYLENETRIAMINEPENTAACETIC ACID IRON III; TREATING ASSOCIATED HYPOTENSION | MOLICHEM MEDICINES, INC. | 2002-10-15 | — | — | US | disclosed |
| US-20020091113-A1 | Treatment of septic shock | MOLICHEM MEDICINES, INC. | 2002-07-11 | — | — | US | disclosed |
| EP-0697864-B1 | USE OF FERRIOXAMINE B IN THE TREATMENT OS SEPTIC SHOCK | MOLICHEM MEDICINES INC (US) | 2000-09-06 | — | — | EP | disclosed |
| EP-0697864-A1 | TREATMENT OF SEPTIC SHOCK | MOLICHEM MEDICINES, INC. (US) | 1996-02-28 | — | — | EP | disclosed |
| WO-1994026263-A2 | USE OF A TRANSITION METAL COMPLEX FOR THE TREATMENT OF SEPTIC SHOCK | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008856-A1 | Treatment of septic shock | MB, NOS2, NOS3 | TDP1 3944/4885MEN1 3276/4885KMT2A 4258/4885 |
| US-20020091113-A1 | Treatment of septic shock | NOS2, MB, NOS3 | TDP1 3987/4885MEN1 3158/4885KMT2A 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.